Literature DB >> 14693600

Are peripheral opioid antagonists the solution to opioid side effects?

John J Bates1, Joseph F Foss, Damian B Murphy.   

Abstract

UNLABELLED: Opioid medication is the mainstay of therapy for severe acute and chronic pain. Unfortunately, the side effects of these medications can affect patient comfort and safety, thus limiting their proven therapeutic potential. Whereas the main analgesic effects of opioids are centrally mediated, many of the common side effects are mediated via peripheral receptors. Novel peripheral opioid antagonists have been recently introduced that can block the peripheral actions of opioids without affecting centrally mediated analgesia. We review the clinical and experimental evidence of their efficacy in ameliorating opioid side effects and consider what further information might be useful in defining their role. IMPLICATIONS: The major analgesic effects of opioid medication are mediated within the brain and spinal cord. Many of the side effects of opioids are caused by activation of receptors outside these areas. Recently developed peripherally restricted opioid antagonists have the ability to block many opioid side effects without affecting analgesia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693600     DOI: 10.1213/01.ane.0000090147.97636.77

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm.

Authors:  J H Kao; S L Chen; H I Ma; P Y Law; P L Tao; H H Loh
Journal:  J Pharmacol Exp Ther       Date:  2010-06-16       Impact factor: 4.030

Review 2.  Tapentadol extended release: in adults with chronic pain.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

3.  Acute oxycodone induces the pro-emetic pica response in rats.

Authors:  Vinita R Batra; Lisa M Schrott
Journal:  J Pharmacol Exp Ther       Date:  2011-08-29       Impact factor: 4.030

Review 4.  Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 5.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

Review 7.  Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor.

Authors:  Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  IUBMB Life       Date:  2010-02       Impact factor: 3.885

8.  14-Methoxymetopon, a highly potent mu opioid agonist, biphasically affects ethanol intake in Sardinian alcohol-preferring rats.

Authors:  Valentina Sabino; Pietro Cottone; Luca Steardo; Helmut Schmidhammer; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

Review 9.  Addressing opioid tolerance and opioid-induced hypersensitivity: Recent developments and future therapeutic strategies.

Authors:  Faris Khan; Aman Mehan
Journal:  Pharmacol Res Perspect       Date:  2021-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.